C2 Blockchain Expands DOG Treasury to 600 Million, Advancing Institutional Adoption of Bitcoin-Native Digital Assets

Rhea-AI Summary

Trinity Capital (Nasdaq: TRIN) announced a $45 million growth capital commitment to Rapid Micro Biosystems (Nasdaq: RPID) to support scaling of the Growth Direct platform and global commercial expansion.

The funding is designated to accelerate manufacturing scale, fund product cost reductions, improve service productivity, and drive gross margin expansion, with the stated goal of strengthening Rapid Micro's financial position and supporting long-term revenue growth and shareholder value.

Positive

• $45 million committed in growth capital to Rapid Micro
• Capital to support global commercial expansion of Growth Direct platform
• Funding targeted to drive gross margin expansion via cost and efficiency initiatives
• Company cites support for long-term revenue growth and shareholder value

Negative

• None.

PHOENIX, Sept. 22, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $45 million in growth capital to Rapid Micro Biosystems (Nasdaq: RPID) ("Rapid Micro"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products.

Rapid Micro specializes in automating microbial quality control in mission-critical applications such as environmental monitoring, water testing, sterility testing, and bioburden testing. The Company's Growth Direct^® platform provides faster results, greater accuracy, increased operational efficiency, and stronger data integrity, enabling customers to make quicker decisions that help ensure a safe and consistent supply of important healthcare products.

"In an industry where quality cannot be compromised, Rapid Micro Biosystems is delivering the automation and dependability manufacturers need," said Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital. "They are transforming a critical process within biopharma manufacturing, and we are proud to partner with a team driving meaningful impact across the industry."

This new capital will help scale Rapid Micro's operations, to include supporting the continued global commercial expansion of the Growth Direct platform, and ongoing investments to drive gross margin expansion through product cost reduction, increased manufacturing efficiencies, and service productivity.

"We are pleased to partner with Trinity Capital, who shares our vision of automating manual microbial quality control testing methods used in biopharma manufacturing," said Robert Spignesi, President and CEO of Rapid Micro Biosystems. "This facility significantly strengthens our financial position and supports our continued focus on long-term revenue growth, margin expansion, and increasing shareholder value."

About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $4.7 billion across over 420 investments since inception in 2008 (As of June 30, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).

About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-45-million-in-growth-capital-to-rapid-micro-biosystems-modernizing-healthcare-industry-practices-302562036.html

SOURCE Trinity Capital Inc.

FAQ

What did Trinity Capital announce about Rapid Micro on November 18, 2025?

Trinity Capital committed $45 million in growth capital to Rapid Micro to support expansion and margin improvement.

How will the $45 million from Trinity Capital be used by Rapid Micro (RPID)?

The funding will support global commercial expansion of the Growth Direct platform, manufacturing efficiencies, product cost reduction, and service productivity to improve gross margins.

Does the announcement state how the $45 million affects Rapid Micro's financial position?

Yes, the company said the facility strengthens its financial position and supports long-term revenue growth and shareholder value.

What product does Rapid Micro plan to scale with Trinity Capital's investment?

Rapid Micro plans to scale its Growth Direct platform, which automates microbial quality control testing for biopharma manufacturing.

Which Nasdaq tickers are mentioned in the announcement?

Trinity Capital is listed as TRIN and Rapid Micro Biosystems is listed as RPID.